Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.14307 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tildrakizumab use for recalcitrant pityriasis rubra pilaris.
Australas J Dermatol
August 2024
Department of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
Evolving Landscape of Biologic Therapy for Pediatric Psoriasis.
Dermatol Clin
July 2024
Department of Dermatology, Weill Cornell Medicine, 1305 York Avenue, 9th Floor, New York, NY 10021, USA. Electronic address:
Article Synopsis
- - Pediatric psoriasis is a long-lasting skin condition that causes inflammation and requires ongoing management.
- - Treatment options include topical treatments, light therapy, and systemic medications, with biological therapies being particularly favorable for moderate-to-severe cases.
- - The article examines currently approved biological treatments for pediatric psoriasis and highlights those that are still being researched.
Comparing quality of life in women with vulvovaginal lichen planus treated with topical and systemic treatments using the vulvar quality of life index.
Australas J Dermatol
May 2023
Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Background/objectives: For patients with vulvovaginal lichen planus (VLP), there exists limited data on the comparison between patient quality of life treated with topical and/or systemic treatments. We characterised the treatment outcomes of VLP using the vulvar quality of life index (VQLI) comparing women treated with systemic immunosuppression, including humanised interleukin-23 monoclonal antibody tildrakizumab, to those treated with topical corticosteroids alone.
Methods: A retrospective cohort study is reported from a dermatology practice in Sydney, Australia.
Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report.
Clin Cosmet Investig Dermatol
August 2022
Aesthetic Dermatology, Sydney, NSW, Australia.
Elevated levels of inflammatory mediators-including the interleukin IL-23-are implicated in the pathogenesis of pyoderma gangrenosum (PG), an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, suppurative ulcers and cribriform scarring. Here, we present the first case report of significant response of isolated ulcerative PG with tildrakizumab, a biologic agent directed against the p19 subunit of IL-23, in an elderly woman with extensive treatment-refractory PG on her left leg. Tildrakizumab (100 mg subcutaneously at weeks 0 and 4, then every 8 weeks, and eventually increased in frequency to every 6 weeks), combined with acetic acid soaks each morning and chemical debridement every evening with 3% hydrogen peroxide, resulted in progressive decrease in ulcer size and depth, re-epithelialization, and recovery of sensory perception.
View Article and Find Full Text PDFSuccessful treatment of vulvovaginal lichen planus with tildrakizumab: A case series of 24 patients.
Australas J Dermatol
May 2022
Department of Dermatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Vulvovaginal lichen planus (VLP) is a chronic inflammatory dermatosis affecting the genital skin and mucosa that can have a profound negative impact on patient quality of life. Up to 43% of women with VLP require systemic immunosuppression to achieve disease remission, and some individuals prove to be highly treatment resistant. We present a case series of 24 women with severe VLP who successfully achieved remission using off-label treatment with the interleukin-23 (IL-23) monoclonal antibody blocker tildrakizumab, and highlight tildrakizumab as a treatment for women with recalcitrant VLP who have failed more conservative treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!